ClinicalTrials.gg
RecruitingNCT05306223PROSPECTUpdated Jan 18, 2023

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

A Phase 4 interventional study of Bedaquiline and Levofloxacin in Tuberculosis, Multidrug-Resistant, sponsored by Beijing Chest Hospital. Recruiting at 17 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Beijing Chest Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant — 3 open to participants now, 5 under way, 3 of them phase 3. bedaquiline · Tuberculosis, Multidrug-Resistant.

Planned enrollment
9th of 20
212 · median 195
Started
2022
with 1 other
Phase 4
Only one
of the 20
Registered
17th of 20
by date
Lead sponsor
1 of 20
Beijing Chest Hospital

Among the 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant, this one is the 9th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 4, and was the 17th registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

3 of the 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bedaquiline

bedaquiline: first FDA approval 2012 (SIRTURO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bedaquiline in Tuberculosis, Multidrug-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not including bedaquiline at the end of treatment in participants with pulmonary MDR-TB in China.

03

Conditions studied

  • Tuberculosis, Multidrug-Resistant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a positive sputum Mycobacterium tuberculosis culture from a test performed at screening
  • Has microbiological confirmation of rifampicin resistance by GeneXpert and to isoniazid (INH) via molecular drug-susceptibility testing (DST) showing katG mutation
  • Has a chest imaging result compatible with a diagnosis of pulmonary Tuberculosis (TB)
  • Agrees to use effective during the 40-week study treatment phase. A female participant must be: of nonchildbearing potential; of and practicing effective methods of contraception during the 40-week study treatment phase
  • Is willing to undergo (HIV) testing

Exclusion criteria

Exclusion Criteria:

  • Has received prior treatment with bedaquiline
  • Has prior exposure to at least 1 drug in the regimen for at least 4 weeks
  • Has any grade 3 or 4 laboratory abnormality as confirmed by a clinical expert
  • Has a known allergy or intolerance to bedaquiline or other drugs in the regimen
  • Is infected with a strain of nontuberculous mycobacteria
  • Is -positive
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Bedaquiline-containing Short-course Regimen (SCR)

    Participants will receive an oral dose of bedaquiline 400 milligrams (mg) once daily for first 2 weeks followed by bedaquiline 200 mg thrice a week for 22 weeks (with at least 48 hours between doses) in combination with oral doses of levofloxacin (LFX) up to 1000 mg (weight-based), cycloserine (CS) up to 750 mg (weight-based), clofazimine (CFZ) 100 mg daily for 40 weeks and linezolid \[LZD\] 600 mg daily for at least 24 weeks . If a participant is still sputum culture-positive for Mycobacterium tuberculosis by Week 16, bedaquiline treatment will be extended from Week 24 to Week 40.

    Drug: Bedaquiline · Drug: Levofloxacin · Drug: Linezolid · Drug: Cycloserine · Drug: Clofazimine

  • Experimental
    Non-bedaquiline-containing Short-course Regimen (SCR)

    Participants will receive oral doses of LFX up to 1000 mg (weight-based), CS up to 750 mg (weight-based), CFZ 100 mg, Pyrazinamide (PZA) up to 2000 mg (weight-based), Protionamide (PTO) up to 800 mg (weight-based) daily for first 16 weeks and LZD 600 mg daily for at least 24 weeks.

    Drug: Levofloxacin · Drug: Linezolid · Drug: Cycloserine · Drug: Clofazimine · Drug: Pyrazinamide · Drug: Protionamide

Interventions

  • Bedaquiline uncoated tablets will be administered orally.

    Also known as: SIRTURO

  • Levofloxacin filmcoated will be administered orally

  • Linezolid tablets will be administered orally

  • Cycloserine capsules will be administered orally.

  • Clofazimine capsules will be administered orally.

  • Pyrazinamide tablets will be administered orally.

  • DrugProtionamide

    Protionamide enteric-coated tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with a Favorable Treatment Outcome at the End of Treatment

    Percentage of participants with a favorable treatment outcome at the end of treatment will be reported. A participant's outcome will be classified as favorable if their last 3 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 3 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.

    Time frame: At the end of treatment (Week 40)

Secondary outcomes

  1. Percentage of Participants with a Favorable Treatment Outcome at 48 Weeks Post the End of Treatment

    Percentage of participants with a favorable treatment outcome at 48 weeks post the end of treatment will be reported. A participant's outcome will be classified as favorable if their last 3 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 3 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.

    Time frame: At 48 weeks post the end of treatment (Week 88)

  2. Percentage of Participants Achieving Treatment Success at the end of Treatment

    Percentage of participants achieving treatment success at the end of treatment will be reported. Treatment success is achieved if participants completed their prescribed tuberculosis (TB) treatment; or if their last 3 culture results are negative by the end of treatment, these 3 cultures must be taken on separate visits and should be after the initial 6-month treatment period.

    Time frame: At the end of treatment (Week 40)

  3. Percentage of Participants with a Modified Favorable Treatment Outcome at the end of Treatment and at 48 Weeks Post end of Treatment

    Percentage of participants with a modified favorable treatment outcome at the end of treatment and at 48 weeks post end of treatment will be reported. A participant's treatment outcome will be classified as modified favorable if their last 2 culture results by the end of treatment are negative unless they have previously been classified as unfavorable. These 2 cultures must be taken on separate visits; the latest of which being no more than 8 weeks prior to the end of treatment.

    Time frame: At the end of treatment (Week 40) and at 48 weeks post end of treatment (Week 88)

  4. Percentage of Participants Experiencing All-cause Mortality

    Percentage of participants experiencing all-cause mortality will be reported.

    Time frame: Up to Week 88

  5. Percentage of Participants Experiencing Grade 3 or Greater Treatment-emergent Adverse Events (TEAEs) During Study Treatment and Follow-up

    Percentage of participants experiencing grade 3 or greater TEAEs during study treatment and follow-up will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any event that begins or worsens in severity after initiation of study drug through to the end of study. An assessment of severity grade will be made using the following 5 general categorical descriptors based on division of acquired immunodeficiency syndrome (AIDS) grading for AE severity assessment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death.

    Time frame: During study treatment and follow-up (From Week 1 up to Week 88)

  6. Percentage of Participants Experiencing TEAEs

    Percentage of participants experiencing TEAEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as any event that begins or worsens in severity after initiation of study drug through to the end of study.

    Time frame: From Week 1 up to Week 88

  7. Percentage of Participants with TB Relapses and Re-infections During the Treatment-free Follow-up Phase

    Percentage of participants with TB relapses and re-infections during the treatment-free follow-up phase will be reported.

    Time frame: During the treatment-free follow-up phase (Up to 48 weeks)

  8. Percentage of Participants Whose Isolates Develop Resistance to Bedaquiline and Other Drugs Used in the Regimen

    Percentage of participants whose isolates develop resistance to bedaquiline and other drugs used in the regimen will be reported.

    Time frame: Up to Week 88

07

Study locations

15 of 17 sites recruiting
  • Beijing Chest Hospital
    Beijing, 101149, China
    Recruiting
    • Mengqiu Gao · Contact
  • The Eighth Medical Center of PLA General Hospital
    Beijing, China
    Recruiting
    • Huiru An · Contact
  • Changsha Central Hospital
    Changsha, China
    Recruiting
    • Yi Pei · Contact
  • Public health clinical medical center of Chengdu
    Chengdu, China
    Recruiting
    • Guihui Wu · Contact
  • Chongqing Public Health Medical Center
    Chongqing, China
    Recruiting
    • Xiaofeng Yan · Contact
  • The Pulmonary Hospital of Fuzhou in Fujian Province(The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province)
    Fuzhou, China
    Recruiting
    • Xiaohong Chen · Contact
  • Guiyang Public Health Clinical Center
    Guiyang, China
    Recruiting
    • Zhongfeng Huang · Contact
  • Anhui Chest Hospital
    Hefei, China
    Recruiting
    • Hua Wang · Contact
  • Infectious Disease Hospital of Heilongjiang Province
    Heilongjiang, China
    Recruiting
    • Long Jin · Contact
  • Jiamusi Tumor Hospital
    Jiamusi, China
    Not yet recruiting
    • Xiujie Li · Contact
  • Jiangxi Chest Hospital
    Jiangxi, China
    Not yet recruiting
    • Yuqing Wu · Contact
  • Shandong public health clinical center
    Shandong, China
    Recruiting
    • Yu Xiong · Contact
  • Shanghai Pulmonary Hospital
    Shanghai, China
    Recruiting
    • Wei Sha · Contact
  • Shenyang Chest Hospital
    Shenyang, China
    Recruiting
    • Lian Shi · Contact
  • Wuhan Pulmonary Hospital
    Wuhan, China
    Recruiting
    • Juan Du · Contact
  • Xi'an Chest Hospital
    Xi'an, China
    Recruiting
    • Fei Ren · Contact
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, China
    Recruiting
    • Junwei Cui · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Aug 2025, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 1, 2022
StartActual
May 10, 2022
Primary completionEst.
Aug 8, 2025
CompletionEst.
Aug 8, 2025
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05306223
Lead sponsor
Beijing Chest Hospital
Responsible party
Gao Mengqiu (Director of Department of Tuberculosis, Beijing Chest Hospital) — Principal investigator
First posted
Apr 1, 2022
Start date
May 10, 2022
Primary completion
Aug 8, 2025 (estimated)
Completion
Aug 8, 2025 (estimated)
Last update
Jan 18, 2023

Study contacts

Jingtao Gao, PhD
Contact
jingtaogao@outlook.com
+8610-89509131
Mengqiu Gao
principal investigator · Beijing Chest Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bedaquiline · Pyrazinamide

Start the discussion